Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEVIN D CANNON

Allopathic & Osteopathic Physicians Hospitalist

NPI
1700897022
CMS profile
122867
Location
WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$58.19

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $32.27 1
Food and Beverage $25.92 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $32.27 1
Boehringer Ingelheim Pharmaceuticals, Inc. $25.92 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEVIN D CANNON

NPI 1700897022 · CMS profile ID 122867

Allopathic & Osteopathic Physicians / Hospitalist

WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $58.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $25.9208/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887506015 CMS
Novo Nordisk Inc $32.2706/08/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898661569 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,301.48 16
PY2021 $20.00 1
PY2022 $58.19 2
PY2023 $1,400.30 14
PY2025 $116.03 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,200.00 1
PY2025 Principal investigator $6,407,903.58 738
PY2024 Recipient $12,299.41 13
PY2024 Principal investigator $7,058,469.69 390
PY2023 Recipient $3,980.00 2
PY2023 Principal investigator $7,125,617.33 899
PY2022 Recipient $9,082.00 12
PY2022 Principal investigator $6,929,547.49 979
PY2021 Recipient $14,312.20 61
PY2021 Principal investigator $9,361,495.59 2,459
PY2020 Recipient $233.41 1
PY2020 Principal investigator $5,812,787.31 750
PY2019 Principal investigator $4,820,055.08 826

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

751 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,820.16 12/31/2020 Non-covered Recipient Entity
Pmg Research Inc
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 736737225
Principal investigator 1 AstraZeneca Pharmaceuticals LP $73.02 12/31/2020 Non-covered Recipient Entity
Pmg Research Of Wilmington
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 736742211
Principal investigator 1 AstraZeneca Pharmaceuticals LP $164.13 12/31/2020 Non-covered Recipient Entity
Pmg Research Of Hickory
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 736745827
Principal investigator 1 Novo Nordisk AS $41.00 12/30/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 822174155
Principal investigator 1 PFIZER INC. $12,842.17 12/30/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742892100
Principal investigator 1 PFIZER INC. $5,670.94 12/29/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742892097
Principal investigator 1 Novo Nordisk AS $41.00 12/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 822174153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $164,332.58 12/24/2020 Non-covered Recipient Entity
PMG RESEARCH
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724481879
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,000.00 12/23/2020 Non-covered Recipient Entity
PMG Research Inc
Ph IIb dose finding vs placebo in patients with Ob No dispute reported 06/30/2026 751191663
Principal investigator 1 Novo Nordisk AS $596.00 12/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177071
Principal investigator 1 Novo Nordisk AS $178.00 12/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177073
Principal investigator 1 Novo Nordisk AS $3,000.00 12/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4477 No dispute reported 06/30/2026 742340833
Principal investigator 1 Novo Nordisk AS $871.33 12/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340837
Principal investigator 1 Novo Nordisk AS $9,448.04 12/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340843
Principal investigator 1 Novo Nordisk AS $14,538.84 12/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340849
Principal investigator 1 Novo Nordisk AS $800.00 12/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340851
Principal investigator 1 Novo Nordisk AS $14,154.48 12/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340861
Principal investigator 1 Novo Nordisk AS $2,579.40 12/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 742340863
Principal investigator 1 Novo Nordisk AS $774.25 12/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340865
Principal investigator 1 Novo Nordisk AS $27.00 12/21/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 822169901
Principal investigator 1 Novo Nordisk AS $41.00 12/21/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 822174159
Principal investigator 1 PFIZER INC. $12,809.82 12/19/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742892039
Principal investigator 1 Novo Nordisk AS $135.00 12/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 822171013
Principal investigator 1 Novo Nordisk AS $41.00 12/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 822174149
Principal investigator 1 Novo Nordisk AS $41.00 12/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 822174151
Principal investigator 1 PFIZER INC. $66,884.40 12/16/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742892359
Principal investigator 1 PFIZER INC. $15,133.19 12/12/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742892043
Principal investigator 1 Novo Nordisk AS $400.00 12/10/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/10/2020 Non-covered Recipient Entity
PMG RESEARCH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724480743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/10/2020 Non-covered Recipient Entity
PMG RESEARCH
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724480745
Principal investigator 1 Novo Nordisk AS $41.00 12/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 822174157
Principal investigator 1 SANOFI US SERVICES INC. $4,200.00 12/09/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise No dispute reported 06/30/2026 744045769
Principal investigator 1 Novo Nordisk AS $41.00 12/08/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 822174147
Principal investigator 1 Merck Sharp & Dohme Corporation $10,500.00 12/07/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON, LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V591 MV SARS-CoV-2, Live, Recombinant in Healthy Individuals 16 Years of Age or Older No dispute reported 06/30/2026 740793303
Principal investigator 1 PFIZER INC. $23,061.72 12/05/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742892093
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176961
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176963
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176965
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176967
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176969
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176971
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176973
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176975
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176977
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176979
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176981
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176983
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176985
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176987
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176989
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176991
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176993
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176995
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176997
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822176999
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177001
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177003
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177005
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177007
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177009
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177011
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177013
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177015
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177017
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177019
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177021
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177023
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177025
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177027
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177029
Principal investigator 1 Novo Nordisk AS $74.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177031
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177033
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177035
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177037
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177039
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177041
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177043
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177045
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177047
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177049
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177051
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177053
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177055
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177057
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177059
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177061
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177063
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177065
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177067
Principal investigator 1 Novo Nordisk AS $33.00 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 822177069
Principal investigator 1 PFIZER INC. $508.00 12/03/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742868325
Principal investigator 1 PFIZER INC. $661.50 12/03/2020 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 742891893
Principal investigator 1 PFIZER INC. $66,798.00 12/03/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742892363
Principal investigator 1 PFIZER INC. $4,630.50 12/03/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742892367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,045.26 12/03/2020 Non-covered Recipient Entity
PMG RESEARCH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724480277
Principal investigator 1 Novo Nordisk AS $41.00 12/02/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 822174145
Principal investigator 1 SANOFI US SERVICES INC. $800.00 12/02/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise No dispute reported 06/30/2026 744045729
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 12/01/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise No dispute reported 06/30/2026 744045737
Principal investigator 1 Novo Nordisk AS $769.50 11/30/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340841
Principal investigator 1 Novo Nordisk AS $5,123.78 11/30/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340845
Principal investigator 1 PFIZER INC. $34,118.63 11/28/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913103
Principal investigator 1 Novo Nordisk AS $1,000.00 11/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 742340853
Principal investigator 1 Novo Nordisk AS $500.00 11/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 742340855
Principal investigator 1 Novo Nordisk AS $20,094.41 11/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 742340857
Principal investigator 1 Novo Nordisk AS $7,045.46 11/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51,658.79 11/25/2020 Non-covered Recipient Entity
PMG RESEARCH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724479713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $897,509.48 11/25/2020 Non-covered Recipient Entity
PMG RESEARCH
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724479715
Principal investigator 1 Novo Nordisk AS $934.57 11/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340835
Principal investigator 1 Novo Nordisk AS $130.00 11/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.62 11/24/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724479627
Principal investigator 1 Novo Nordisk AS $41.06 11/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $518.98 11/23/2020 Non-covered Recipient Entity
PMG RESEARCH
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724479471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.76 11/23/2020 Non-covered Recipient Entity
PMG RESEARCH
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724479473
Principal investigator 1 PFIZER INC. $268,739.95 11/21/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742854603
Principal investigator 1 PFIZER INC. $997.51 11/21/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742868037
Principal investigator 1 PFIZER INC. $74,438.76 11/21/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913135
Principal investigator 1 PFIZER INC. $15,214.50 11/21/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742920047
Principal investigator 1 Novo Nordisk AS $0.30 11/20/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340871
Principal investigator 1 Novo Nordisk AS $5.72 11/20/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340873
Principal investigator 1 Novo Nordisk AS $325.80 11/20/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340875
Principal investigator 1 Novo Nordisk AS $891.00 11/20/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340877
Principal investigator 1 Novo Nordisk AS $439.20 11/20/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340879
Principal investigator 1 PFIZER INC. $4,630.50 11/19/2020 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 742920367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,560.48 11/19/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724479203
Principal investigator 1 Novo Nordisk AS $75.00 11/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340739
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340881
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340883
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340885
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340887
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340889
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340891
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340893
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340895
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340897
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340899
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340901
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340903
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340905
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340907
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340909
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340911
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340913
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340915
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340917
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340919
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340921
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340923
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340925
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340927
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340929
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340931
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340933
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340935
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340937
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340939
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340941
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340943
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340945
Principal investigator 1 Novo Nordisk AS $3.05 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340947
Principal investigator 1 Novo Nordisk AS $1.95 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340949
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340951
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340953
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340955
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340957
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340959
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340961
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340963
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340965
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340967
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340969
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340971
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340973
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340975
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340977
Principal investigator 1 Novo Nordisk AS $9.98 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340979
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340981
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340983
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340985
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340987
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340989
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340991
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340993
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340995
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340997
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742340999
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341001
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341003
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341005
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341007
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341009
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341011
Principal investigator 1 Novo Nordisk AS $5.30 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341013
Principal investigator 1 Novo Nordisk AS $3.02 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341015
Principal investigator 1 Novo Nordisk AS $22.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341017
Principal investigator 1 Novo Nordisk AS $8.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341019
Principal investigator 1 Novo Nordisk AS $72.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341021
Principal investigator 1 Novo Nordisk AS $3.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341023
Principal investigator 1 Novo Nordisk AS $39.90 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341025
Principal investigator 1 Novo Nordisk AS $6.50 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341027
Principal investigator 1 Novo Nordisk AS $9.74 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341029
Principal investigator 1 Novo Nordisk AS $40.00 11/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
NN1436-4477 No dispute reported 06/30/2026 742341031
Principal investigator 1 PFIZER INC. $76,590.12 11/17/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742912917
Principal investigator 1 PFIZER INC. $2,678.00 11/16/2020 Non-covered Recipient Entity
PMG Research of WilmingtonLLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742870793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29,697.99 11/16/2020 Non-covered Recipient Entity
PMG RESEARCH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724479039
Principal investigator 1 Novo Nordisk AS $41.06 11/13/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340743
Principal investigator 1 PFIZER INC. $45,777.56 11/11/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913139
Principal investigator 1 Eli Lilly and Company $32.56 11/09/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 728745059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $818.28 11/09/2020 Non-covered Recipient Entity
PMG RESEARCH
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724478721
Principal investigator 1 Merck Sharp & Dohme Corporation $19,479.60 11/06/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727263
Principal investigator 1 Novo Nordisk AS $562.00 11/05/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4477 No dispute reported 06/30/2026 742340867
Principal investigator 1 Novo Nordisk AS $1,182.00 11/05/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4477 No dispute reported 06/30/2026 742340869
Principal investigator 1 Novo Nordisk AS $41.06 11/03/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340741
Principal investigator 1 PFIZER INC. $131,102.55 10/31/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913099
Recipient Eli Lilly and Company $233.41 10/29/2020 Covered Recipient Physician A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 728722147
Principal investigator 1 Novo Nordisk AS $9,876.46 10/29/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340761
Principal investigator 1 Novo Nordisk AS $1,987.89 10/29/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340765
Principal investigator 1 Novo Nordisk AS $187.50 10/29/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340767
Principal investigator 1 Novo Nordisk AS $13,360.01 10/29/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340777
Principal investigator 1 Novo Nordisk AS $738.13 10/29/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340789
Principal investigator 1 Novo Nordisk AS $1,267.52 10/29/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340791
Principal investigator 1 Novo Nordisk AS $1,187.50 10/29/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340803
Principal investigator 1 PFIZER INC. $7,276.50 10/29/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742920229
Principal investigator 1 Novo Nordisk AS $41.06 10/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340637
Principal investigator 1 Novo Nordisk AS $41.06 10/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340633
Principal investigator 1 Novo Nordisk AS $130.00 10/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,230.45 10/27/2020 Non-covered Recipient Entity
PMG RESEARCH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724478007
Principal investigator 1 PFIZER INC. $96,175.67 10/23/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742912923
Principal investigator 1 Novo Nordisk AS $41.06 10/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340727
Principal investigator 1 PFIZER INC. $37,725.40 10/22/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742920371
Principal investigator 1 PFIZER INC. $1,985.38 10/22/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742920553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $397,108.65 10/22/2020 Non-covered Recipient Entity
PMG RESEARCH
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 No dispute reported 06/30/2026 724477797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.62 10/22/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724477885
Principal investigator 1 PFIZER INC. $92,690.35 10/20/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913095
Principal investigator 1 Novo Nordisk AS $41.06 10/19/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340635
Principal investigator 1 PFIZER INC. $1,773.90 10/17/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742868039
Principal investigator 1 PFIZER INC. $10,584.00 10/17/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742920551
Principal investigator 1 Novo Nordisk AS $41.06 10/16/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340725
Principal investigator 1 PFIZER INC. $156,267.38 10/10/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742913049
Principal investigator 1 Merck Sharp & Dohme Corporation $2,778.00 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727265
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340611
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340613
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340615
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340617
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340619
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340621
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340623
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340625
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340627
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340629
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340631
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340639
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340641
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340643
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340645
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340647
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340649
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340651
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340653
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340655
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340657
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340659
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340661
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340663
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340665
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340667
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340669
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340671
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340673
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340675
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340677
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340679
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340681
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340683
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340685
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340687
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340689
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340691
Principal investigator 1 Novo Nordisk AS $33.15 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340693
Principal investigator 1 Novo Nordisk AS $749.75 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340695
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340697
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340699
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340701
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340703
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340705
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340707
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340709
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340711
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340713
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340715
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340717
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340719
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340721
Principal investigator 1 Novo Nordisk AS $73.97 10/09/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 10/08/2020 Non-covered Recipient Entity
PMG RESEARCH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724476635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 10/08/2020 Non-covered Recipient Entity
PMG RESEARCH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724476639
Principal investigator 1 Novo Nordisk AS $41.06 10/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340829
Principal investigator 1 Novo Nordisk AS $41.06 10/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340831
Principal investigator 1 Novo Nordisk AS $41.06 10/02/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340827
Principal investigator 1 PFIZER INC. $25,361.20 10/02/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742868043
Principal investigator 1 PFIZER INC. $191,330.42 10/02/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742912921
Principal investigator 1 GlaxoSmithKline, LLC. $5,756.40 10/01/2020 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734915555
Principal investigator 1 GlaxoSmithKline, LLC. $2,878.20 10/01/2020 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734923357
Principal investigator 1 GlaxoSmithKline, LLC. $2,878.20 10/01/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965523551
Principal investigator 1 GlaxoSmithKline, LLC. $5,756.40 10/01/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965523559
Principal investigator 1 PFIZER INC. $5,953.50 10/01/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742920465
Principal investigator 1 PFIZER INC. $200.00 10/01/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742920557
Principal investigator 1 Novo Nordisk AS $41.06 09/30/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340807
Principal investigator 1 Novo Nordisk AS $41.06 09/30/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340809
Principal investigator 1 Novo Nordisk AS $41.06 09/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340805
Principal investigator 1 PFIZER INC. $204,892.68 09/26/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742943905
Principal investigator 1 Novo Nordisk AS $7,877.33 09/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340775
Principal investigator 1 Novo Nordisk AS $11,408.14 09/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340783
Principal investigator 1 Novo Nordisk AS $279.30 09/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340785
Principal investigator 1 Novo Nordisk AS $200.00 09/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340787
Principal investigator 1 Novo Nordisk AS $2,698.01 09/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340801
Principal investigator 1 Novo Nordisk AS $41.06 09/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340817
Principal investigator 1 Novo Nordisk AS $41.06 09/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340811
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 09/23/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045645
Principal investigator 1 Novo Nordisk AS $2,536.79 09/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340755
Principal investigator 1 Novo Nordisk AS $260.00 09/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340757
Principal investigator 1 Novo Nordisk AS $1,245.69 09/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340763
Principal investigator 1 Novo Nordisk AS $644.85 09/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 742340797
Principal investigator 1 Novo Nordisk AS $41.06 09/21/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340819
Principal investigator 1 PFIZER INC. $13,058.52 09/19/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742920051
Principal investigator 1 PFIZER INC. $142,759.06 09/19/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742943841
Principal investigator 1 Merck Sharp & Dohme Corporation $1,839.00 09/18/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727233
Principal investigator 1 Novo Nordisk AS $41.06 09/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340813
Principal investigator 1 Novo Nordisk AS $41.06 09/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,759.95 09/17/2020 Non-covered Recipient Entity
PMG RESEARCH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724475111
Principal investigator 1 PFIZER INC. $197,634.64 09/12/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742943847
Principal investigator 1 Novo Nordisk AS $23.46 09/11/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340823
Principal investigator 1 PFIZER INC. $161,575.47 09/10/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742944167
Principal investigator 1 PFIZER INC. $4,759.47 09/09/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742855521
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 09/04/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045621
Principal investigator 1 PFIZER INC. $3,172.98 09/03/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742855597
Principal investigator 1 Novo Nordisk AS $48,702.77 09/01/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742340749
Principal investigator 1 Novo Nordisk AS $0.32 09/01/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340821
Principal investigator 1 Novo Nordisk AS $23.46 09/01/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340825
Principal investigator 1 PFIZER INC. $1,586.49 08/31/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742855523
Principal investigator 1 PFIZER INC. $85,273.53 08/29/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742943907
Principal investigator 1 Novo Nordisk AS $500.00 08/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742340745
Principal investigator 1 Novo Nordisk AS $1,000.00 08/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742340747
Principal investigator 1 Novo Nordisk AS $9,340.60 08/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340751
Principal investigator 1 Novo Nordisk AS $520.00 08/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340753
Principal investigator 1 Novo Nordisk AS $12,345.29 08/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340773
Principal investigator 1 Novo Nordisk AS $10,919.87 08/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340779
Principal investigator 1 Novo Nordisk AS $200.00 08/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340781
Principal investigator 1 Novo Nordisk AS $2,901.82 08/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 742340793
Principal investigator 1 Novo Nordisk AS $300.00 08/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 742340795
Principal investigator 1 Novo Nordisk AS $774.25 08/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340799
Principal investigator 1 Novo Nordisk AS $23.46 08/26/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340597
Principal investigator 1 Novo Nordisk AS $23.46 08/26/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.62 08/26/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724474151
Principal investigator 1 Novo Nordisk AS $23.46 08/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340589
Principal investigator 1 Novo Nordisk AS $2,149.37 08/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340769
Principal investigator 1 Novo Nordisk AS $1,050.94 08/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340771
Principal investigator 1 PFIZER INC. $96,977.74 08/22/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742944165
Principal investigator 1 Novo Nordisk AS $27.96 08/21/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340607
Principal investigator 1 Novo Nordisk AS $23.46 08/21/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340609
Principal investigator 1 Astellas Pharma Global Development $8,349.00 08/20/2020 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
PHASE 1/2 STUDY OF ASP2215 (GILTERITINIB) COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR TREATMENT REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML) No dispute reported 06/30/2026 721320947
Principal investigator 1 PFIZER INC. $22,491.00 08/19/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742944069
Principal investigator 1 SANOFI US SERVICES INC. $17,416.00 08/17/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 744017460
Principal investigator 1 Novo Nordisk AS $27.96 08/14/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340601
Principal investigator 1 Novo Nordisk AS $23.46 08/14/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340603
Principal investigator 1 Novo Nordisk AS $23.46 08/14/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $225.00 08/13/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724473323
Principal investigator 1 Merck Sharp & Dohme Corporation $7,359.20 08/12/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727225
Principal investigator 1 SANOFI US SERVICES INC. $3,953.25 08/12/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045637
Principal investigator 1 PFIZER INC. $1,339.00 08/11/2020 Non-covered Recipient Entity
PMG Research of WilmingtonLLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742868321
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,050.00 08/10/2020 Non-covered Recipient Entity
PMG RESEARCH INC
EFC-14837 No dispute reported 06/30/2026 752054539
Principal investigator 1 Novo Nordisk AS $142.89 08/05/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340593
Principal investigator 1 Novo Nordisk AS $73.37 08/05/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340595
Principal investigator 1 Novo Nordisk AS $23.46 08/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340585
Principal investigator 1 Novo Nordisk AS $23.46 08/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340587
Principal investigator 1 Novo Nordisk AS $23.46 08/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340591
Principal investigator 1 PFIZER INC. $18,160.50 08/01/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742944163
Principal investigator 1 Novo Nordisk AS $90.93 07/31/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340733
Principal investigator 1 Novo Nordisk AS $46.69 07/31/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340735
Principal investigator 1 Novo Nordisk AS $2,375.00 07/30/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340499
Principal investigator 1 Novo Nordisk AS $200.00 07/30/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340501
Principal investigator 1 Novo Nordisk AS $15,606.82 07/30/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340523
Principal investigator 1 Novo Nordisk AS $8,246.30 07/30/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340533
Principal investigator 1 Novo Nordisk AS $750.00 07/30/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340535
Principal investigator 1 PFIZER INC. $8,000.00 07/30/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742868319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,112.18 07/29/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724472403
Principal investigator 1 Novo Nordisk AS $2,425.49 07/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340505
Principal investigator 1 Novo Nordisk AS $200.00 07/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340507
Principal investigator 1 Novo Nordisk AS $3,676.65 07/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340513
Principal investigator 1 Novo Nordisk AS $130.00 07/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340515
Principal investigator 1 Novo Nordisk AS $300.00 07/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340517
Principal investigator 1 Novo Nordisk AS $90.93 07/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340729
Principal investigator 1 Novo Nordisk AS $46.69 07/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $34,016.88 07/27/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724471799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.62 07/23/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724471339
Principal investigator 1 PFIZER INC. $31,164.75 07/17/2020 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 742944113
Principal investigator 1 PFIZER INC. $19,385.86 07/17/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742944119
Principal investigator 1 Merck Sharp & Dohme Corporation $38.23 07/15/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727151
Principal investigator 1 Merck Sharp & Dohme Corporation $4,490.80 07/15/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727153
Principal investigator 1 PFIZER INC. $669.50 07/13/2020 Non-covered Recipient Entity
PMG Research of WilmingtonLLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742868155
Principal investigator 1 SANOFI US SERVICES INC. $803.25 07/10/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045631
Principal investigator 1 PFIZER INC. $10,500.00 07/04/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742943845
Principal investigator 1 PFIZER INC. $10,054.72 07/02/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742944117
Principal investigator 1 PFIZER INC. $669.50 06/29/2020 Non-covered Recipient Entity
PMG Research of WilmingtonLLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742868153
Principal investigator 1 Novo Nordisk AS $1,786.00 06/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340509
Principal investigator 1 Novo Nordisk AS $300.00 06/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340511
Principal investigator 1 Novo Nordisk AS $200.00 06/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340531
Principal investigator 1 PFIZER INC. $3,606.75 06/25/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 742935110
Principal investigator 1 Novo Nordisk AS $900.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340539
Principal investigator 1 Novo Nordisk AS $900.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340541
Principal investigator 1 Novo Nordisk AS $900.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340543
Principal investigator 1 Novo Nordisk AS $900.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340545
Principal investigator 1 Novo Nordisk AS $900.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340547
Principal investigator 1 Novo Nordisk AS $900.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340549
Principal investigator 1 Novo Nordisk AS $900.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340551
Principal investigator 1 Novo Nordisk AS $900.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340553
Principal investigator 1 Novo Nordisk AS $900.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340555
Principal investigator 1 Novo Nordisk AS $900.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340557
Principal investigator 1 Novo Nordisk AS $900.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340559
Principal investigator 1 Novo Nordisk AS $900.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340561
Principal investigator 1 Novo Nordisk AS $64.16 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340563
Principal investigator 1 Novo Nordisk AS $36.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340565
Principal investigator 1 Novo Nordisk AS $10.60 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340567
Principal investigator 1 Novo Nordisk AS $2.24 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340569
Principal investigator 1 Novo Nordisk AS $19.60 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340571
Principal investigator 1 Novo Nordisk AS $120.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340573
Principal investigator 1 Novo Nordisk AS $13.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340575
Principal investigator 1 Novo Nordisk AS $18.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340577
Principal investigator 1 Novo Nordisk AS $72.00 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,589.41 06/24/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724468589
Principal investigator 1 Novo Nordisk AS $1,632.82 06/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340497
Principal investigator 1 Novo Nordisk AS $2,247.37 06/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340503
Principal investigator 1 Novo Nordisk AS $529.87 06/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 742340519
Principal investigator 1 Novo Nordisk AS $14,279.73 06/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340521
Principal investigator 1 Novo Nordisk AS $10,444.00 06/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340529
Principal investigator 1 Novo Nordisk AS $912.38 06/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742340537
Principal investigator 1 PFIZER INC. $34,883.74 06/16/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742944067
Principal investigator 1 PFIZER INC. $2,678.00 06/15/2020 Non-covered Recipient Entity
PMG Research of WilmingtonLLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742868149
Principal investigator 1 SANOFI US SERVICES INC. $6,050.00 06/10/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045685
Principal investigator 1 Novo Nordisk AS $2.99 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340581
Principal investigator 1 Novo Nordisk AS $23.46 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340583
Principal investigator 1 Novo Nordisk AS $1,250.00 06/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
INS-4391 No dispute reported 06/30/2026 742340525
Principal investigator 1 Novo Nordisk AS $3,000.00 06/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
INS-4391 No dispute reported 06/30/2026 742340527
Principal investigator 1 PFIZER INC. $28,934.01 06/04/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742941499
Principal investigator 1 PFIZER INC. $28,512.89 06/04/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 742941501
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,034.00 06/01/2020 Non-covered Recipient Entity
Pmg Research Of Hickory
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 736750415
Principal investigator 1 Novo Nordisk AS $1,774.42 05/29/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340153
Principal investigator 1 Novo Nordisk AS $466.29 05/29/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340155
Principal investigator 1 PFIZER INC. $33,998.98 05/29/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742965095
Principal investigator 1 Novo Nordisk AS $9,189.05 05/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340187
Principal investigator 1 Novo Nordisk AS $400.00 05/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340189
Principal investigator 1 Novo Nordisk AS $9,208.26 05/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 742340209
Principal investigator 1 Novo Nordisk AS $703.29 05/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340219
Principal investigator 1 Novo Nordisk AS $3,491.83 05/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340229
Principal investigator 1 Novo Nordisk AS $17,907.59 05/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340243
Principal investigator 1 Novo Nordisk AS $187.50 05/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340245
Principal investigator 1 SANOFI US SERVICES INC. $1,350.00 05/28/2020 Non-covered Recipient Entity
Pmg Research,Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 744017703
Principal investigator 1 Novo Nordisk AS $144.09 05/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,797.00 05/27/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724465467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,996.70 05/27/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724465471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,206.30 05/27/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724465479
Principal investigator 1 Novo Nordisk AS $1,589.62 05/26/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 742340169
Principal investigator 1 Novo Nordisk AS $3,648.41 05/26/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742340199
Principal investigator 1 PFIZER INC. $10,045.90 05/21/2020 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 742965099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,380.55 05/21/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724464389
Principal investigator 1 GlaxoSmithKline, LLC. $1,458.90 05/20/2020 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734904697
Principal investigator 1 PFIZER INC. $13,579.72 05/15/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 742934803
Principal investigator 1 PFIZER INC. $23,944.26 05/15/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742965171
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727155
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727157
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727159
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727161
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727165
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727167
Principal investigator 1 Merck Sharp & Dohme Corporation $35.50 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727169
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727171
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727173
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727175
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727189
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727191
Principal investigator 1 Merck Sharp & Dohme Corporation $297.00 05/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727193
Principal investigator 1 PFIZER INC. $33,883.47 05/08/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742934147
Principal investigator 1 Novo Nordisk AS $1.99 05/07/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340373
Principal investigator 1 Novo Nordisk AS $2.99 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340375
Principal investigator 1 Novo Nordisk AS $23.06 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340377
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340379
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340381
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340383
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340385
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340387
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340389
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340391
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340393
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340395
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340397
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340399
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340401
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340403
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340405
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340407
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340409
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340411
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340413
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340415
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340417
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340419
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340421
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340423
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340425
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340427
Principal investigator 1 Novo Nordisk AS $33.15 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340429
Principal investigator 1 Novo Nordisk AS $202.50 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340431
Principal investigator 1 Novo Nordisk AS $417.50 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340433
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340435
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340437
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340439
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340441
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340443
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340445
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340447
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340449
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340451
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340453
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340455
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340457
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340459
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340461
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340463
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340465
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340467
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340469
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340471
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340473
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340475
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340477
Principal investigator 1 Novo Nordisk AS $73.97 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340479
Principal investigator 1 Novo Nordisk AS $17.40 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340481
Principal investigator 1 Novo Nordisk AS $17.40 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340483
Principal investigator 1 Novo Nordisk AS $17.40 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340485
Principal investigator 1 Novo Nordisk AS $17.40 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340487
Principal investigator 1 Novo Nordisk AS $17.40 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340489
Principal investigator 1 Novo Nordisk AS $17.40 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340491
Principal investigator 1 Novo Nordisk AS $17.40 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340493
Principal investigator 1 Novo Nordisk AS $17.40 05/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340495
Principal investigator 1 SANOFI US SERVICES INC. $1,350.00 05/04/2020 Non-covered Recipient Entity
Pmg Research Of Wilmington
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 744017695
Principal investigator 1 PFIZER INC. $19,345.16 05/01/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742964927
Principal investigator 1 Novo Nordisk AS $10,964.31 04/30/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340185
Principal investigator 1 PFIZER INC. $20,103.75 04/30/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 742937433
Principal investigator 1 PFIZER INC. $8,983.92 04/30/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742965227
Principal investigator 1 SANOFI US SERVICES INC. $6,609.75 04/29/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045679
Principal investigator 1 Novo Nordisk AS $75.00 04/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340361
Principal investigator 1 Novo Nordisk AS $75.00 04/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340363
Principal investigator 1 Novo Nordisk AS $75.00 04/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340365
Principal investigator 1 Novo Nordisk AS $5,291.95 04/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340149
Principal investigator 1 Novo Nordisk AS $130.00 04/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340151
Principal investigator 1 Novo Nordisk AS $5,664.67 04/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 742340167
Principal investigator 1 Novo Nordisk AS $14,947.97 04/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742340197
Principal investigator 1 Novo Nordisk AS $2,731.29 04/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 742340207
Principal investigator 1 Novo Nordisk AS $1,530.39 04/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340217
Principal investigator 1 Novo Nordisk AS $14,720.53 04/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340225
Principal investigator 1 Novo Nordisk AS $5,100.00 04/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340227
Principal investigator 1 Novo Nordisk AS $13,404.56 04/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.31 04/22/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724461643
Principal investigator 1 PFIZER INC. $38,762.66 04/21/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742965231
Principal investigator 1 PFIZER INC. $2,069.55 04/21/2020 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 742965233
Principal investigator 1 AstraZeneca Pharmaceuticals LP $460.00 04/20/2020 Non-covered Recipient Entity
Pmg Research Of Wilmington
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 736739283
Principal investigator 1 Merck Sharp & Dohme Corporation $250.00 04/17/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727145
Principal investigator 1 Novo Nordisk AS $808.32 04/16/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN8022-4272 No dispute reported 06/30/2026 742340171
Principal investigator 1 Merck Sharp & Dohme Corporation $17,862.40 04/15/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727149
Principal investigator 1 GlaxoSmithKline, LLC. $1,159.20 04/08/2020 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734901981
Principal investigator 1 Merck Sharp & Dohme Corporation $297.00 04/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727163
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 04/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,705.27 04/08/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724460151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27,027.00 04/08/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724460161
Principal investigator 1 Novo Nordisk AS $360.00 04/07/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340339
Principal investigator 1 Novo Nordisk AS $360.00 04/07/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340341
Principal investigator 1 Novo Nordisk AS $360.00 04/07/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340343
Principal investigator 1 Novo Nordisk AS $360.00 04/07/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340345
Principal investigator 1 Novo Nordisk AS $360.00 04/07/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340347
Principal investigator 1 Novo Nordisk AS $360.00 04/07/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340349
Principal investigator 1 Novo Nordisk AS $360.00 04/07/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340351
Principal investigator 1 Novo Nordisk AS $360.00 04/07/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340353
Principal investigator 1 Novo Nordisk AS $360.00 04/07/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340355
Principal investigator 1 Novo Nordisk AS $360.00 04/07/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340357
Principal investigator 1 Novo Nordisk AS $360.00 04/07/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340359
Principal investigator 1 GlaxoSmithKline, LLC. $1,378.80 04/01/2020 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734900635
Principal investigator 1 GlaxoSmithKline, LLC. $2,398.50 04/01/2020 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734900869
Principal investigator 1 PFIZER INC. $513.00 04/01/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 742934139
Principal investigator 1 Novo Nordisk AS $2,582.34 03/26/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 742340165
Principal investigator 1 Novo Nordisk AS $14,245.29 03/26/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 742340205
Principal investigator 1 Novo Nordisk AS $2,127.25 03/26/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340221
Principal investigator 1 Novo Nordisk AS $372.75 03/26/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340223
Principal investigator 1 GlaxoSmithKline, LLC. $1,398.60 03/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 753908543
Principal investigator 1 GlaxoSmithKline, LLC. $1,159.20 03/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 753908611
Principal investigator 1 GlaxoSmithKline, LLC. $1,539.00 03/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 753908863
Principal investigator 1 GlaxoSmithKline, LLC. $1,458.90 03/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 753910163
Principal investigator 1 GlaxoSmithKline, LLC. $1,539.00 03/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965523549
Principal investigator 1 GlaxoSmithKline, LLC. $1,159.20 03/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965523553
Principal investigator 1 SANOFI US SERVICES INC. $2,253.25 03/25/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045513
Principal investigator 1 Novo Nordisk AS $2,217.46 03/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340143
Principal investigator 1 Novo Nordisk AS $600.00 03/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340145
Principal investigator 1 Novo Nordisk AS $5,572.51 03/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340147
Principal investigator 1 Novo Nordisk AS $20,353.62 03/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340181
Principal investigator 1 Novo Nordisk AS $1,200.00 03/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340183
Principal investigator 1 Novo Nordisk AS $6,421.36 03/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742340195
Principal investigator 1 Novo Nordisk AS $1,487.64 03/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340215
Principal investigator 1 Novo Nordisk AS $29,624.70 03/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340239
Principal investigator 1 PFIZER INC. $18,435.94 03/19/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742965173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,560.48 03/19/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724458231
Principal investigator 1 GlaxoSmithKline, LLC. $4,775.40 03/18/2020 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 753908605
Principal investigator 1 GlaxoSmithKline, LLC. $1,458.90 03/18/2020 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 753909545
Principal investigator 1 GlaxoSmithKline, LLC. $4,775.40 03/18/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965523557
Principal investigator 1 PFIZER INC. $327.04 03/18/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 742937965
Principal investigator 1 PFIZER INC. $2,069.55 03/18/2020 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 742965175
Principal investigator 1 Merck Sharp & Dohme Corporation $15,627.00 03/16/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727109
Principal investigator 1 Novo Nordisk AS $23.06 03/16/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340367
Principal investigator 1 SANOFI US SERVICES INC. $255.00 03/13/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045507
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $675.00 03/12/2020 Non-covered Recipient Entity
PMG RESEARCH INC
EFC-14868 No dispute reported 06/30/2026 752054549
Principal investigator 1 PFIZER INC. $4,356.75 03/12/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742937703
Principal investigator 1 PFIZER INC. $65.00 03/12/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742962421
Principal investigator 1 PFIZER INC. $50.00 03/12/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742965093
Principal investigator 1 PFIZER INC. $375.00 03/12/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742965391
Principal investigator 1 SANOFI US SERVICES INC. $8,284.00 03/12/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 744017633
Principal investigator 1 SANOFI US SERVICES INC. $1,350.00 03/12/2020 Non-covered Recipient Entity
Pmg Research Of Wilmington
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 744017639
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,224.37 03/11/2020 Non-covered Recipient Entity
Pmg Research Of Wilmington
Phase II study of BI456906 in Patients with T2DM O No dispute reported 06/30/2026 751190693
Principal investigator 1 GlaxoSmithKline, LLC. $1,458.90 03/11/2020 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 753909661
Principal investigator 1 GlaxoSmithKline, LLC. $1,458.90 03/11/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965523563
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,500.00 03/09/2020 Non-covered Recipient Entity
PMG Research Inc
Phase II study of BI456906 in Patients with T2DM O No dispute reported 06/30/2026 751190717
Principal investigator 1 Novo Nordisk AS $7.98 03/06/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340337
Principal investigator 1 SANOFI US SERVICES INC. $85.00 03/06/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045339
Principal investigator 1 SANOFI US SERVICES INC. $700.00 03/06/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38,469.56 03/05/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724456883
Principal investigator 1 SANOFI US SERVICES INC. $3,600.00 03/05/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 744017667
Principal investigator 1 GlaxoSmithKline, LLC. $1,378.80 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 753908115
Principal investigator 1 GlaxoSmithKline, LLC. $1,378.80 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965523555
Principal investigator 1 Novo Nordisk AS $24.95 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340305
Principal investigator 1 Novo Nordisk AS $24.95 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340307
Principal investigator 1 Novo Nordisk AS $24.95 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340309
Principal investigator 1 Novo Nordisk AS $24.95 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340311
Principal investigator 1 Novo Nordisk AS $24.95 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340313
Principal investigator 1 Novo Nordisk AS $24.95 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340315
Principal investigator 1 Novo Nordisk AS $24.95 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340317
Principal investigator 1 Novo Nordisk AS $24.95 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340319
Principal investigator 1 Novo Nordisk AS $24.95 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340321
Principal investigator 1 Novo Nordisk AS $7.95 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340323
Principal investigator 1 Novo Nordisk AS $74.97 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340325
Principal investigator 1 Novo Nordisk AS $13.50 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340327
Principal investigator 1 Novo Nordisk AS $90.00 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340329
Principal investigator 1 Novo Nordisk AS $9.75 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340331
Principal investigator 1 Novo Nordisk AS $13.50 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340333
Principal investigator 1 Novo Nordisk AS $54.00 03/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 742340335
Principal investigator 1 SANOFI US SERVICES INC. $225.00 03/02/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045337
Principal investigator 1 PFIZER INC. $3,606.75 02/28/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 742937055
Principal investigator 1 PFIZER INC. $4,911.80 02/28/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742979565
Principal investigator 1 Novo Nordisk AS $14,083.39 02/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340175
Principal investigator 1 Novo Nordisk AS $300.00 02/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340177
Principal investigator 1 Novo Nordisk AS $187.50 02/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340179
Principal investigator 1 Novo Nordisk AS $29,749.63 02/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 742340203
Principal investigator 1 SANOFI US SERVICES INC. $5,403.25 02/26/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045323
Principal investigator 1 SANOFI US SERVICES INC. $4,500.00 02/26/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045329
Principal investigator 1 Novo Nordisk AS $5,978.78 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340139
Principal investigator 1 Novo Nordisk AS $300.00 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340141
Principal investigator 1 Novo Nordisk AS $3,271.80 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 742340159
Principal investigator 1 Novo Nordisk AS $187.50 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 742340161
Principal investigator 1 Novo Nordisk AS $940.00 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 742340163
Principal investigator 1 Novo Nordisk AS $13,051.21 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742340193
Principal investigator 1 Novo Nordisk AS $4,254.81 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340213
Principal investigator 1 Novo Nordisk AS $23,528.66 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340233
Principal investigator 1 Novo Nordisk AS $2,000.00 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340235
Principal investigator 1 Novo Nordisk AS $375.00 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340237
Principal investigator 1 PFIZER INC. $459.00 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 742979095
Principal investigator 1 PFIZER INC. $532.24 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 742980037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,468.99 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724456045
Principal investigator 1 PFIZER INC. $1,635.20 02/21/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 742937375
Principal investigator 1 PFIZER INC. $11,683.56 02/21/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742979527
Principal investigator 1 GlaxoSmithKline, LLC. $3,496.50 02/19/2020 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734927433
Principal investigator 1 GlaxoSmithKline, LLC. $3,496.50 02/19/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965523565
Principal investigator 1 Novo Nordisk AS $9.99 02/19/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340301
Principal investigator 1 Novo Nordisk AS $23.06 02/19/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340303
Principal investigator 1 PFIZER INC. $480.94 02/19/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742980032
Principal investigator 1 Novo Nordisk AS $33.15 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340251
Principal investigator 1 Novo Nordisk AS $174.75 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340253
Principal investigator 1 Novo Nordisk AS $450.00 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340255
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340257
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340259
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340261
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340263
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340265
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340267
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340269
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340271
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340273
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340275
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340277
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340279
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340281
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340283
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340285
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340287
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340289
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340291
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340293
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340295
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340297
Principal investigator 1 Novo Nordisk AS $73.97 02/18/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340299
Principal investigator 1 Novo Nordisk AS $23.06 02/12/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340249
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,050.00 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH INC
EFC-14838 No dispute reported 06/30/2026 752054541
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727117
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727119
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727121
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727123
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727125
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727127
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727129
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727131
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727133
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727139
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727143
Principal investigator 1 Novo Nordisk AS $24.99 02/04/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340247
Principal investigator 1 Merck Sharp & Dohme Corporation $200.00 02/03/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727115
Principal investigator 1 SANOFI US SERVICES INC. $6,103.25 02/03/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045316
Principal investigator 1 PFIZER INC. $2,632.89 02/01/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742937051
Principal investigator 1 PFIZER INC. $16,749.06 02/01/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742979531
Principal investigator 1 PFIZER INC. $1,635.20 01/31/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 742937333
Principal investigator 1 PFIZER INC. $750.00 01/30/2020 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 742979987
Principal investigator 1 Merck Sharp & Dohme Corporation $5,302.00 01/29/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727111
Principal investigator 1 Novo Nordisk AS $300.00 01/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340135
Principal investigator 1 Novo Nordisk AS $1,655.37 01/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 742340137
Principal investigator 1 Novo Nordisk AS $4,786.22 01/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 742340157
Principal investigator 1 Novo Nordisk AS $8,718.24 01/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340173
Principal investigator 1 Novo Nordisk AS $14,078.17 01/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742340191
Principal investigator 1 Novo Nordisk AS $17,701.05 01/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 742340201
Principal investigator 1 Novo Nordisk AS $5,415.31 01/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 742340211
Principal investigator 1 Novo Nordisk AS $26,839.11 01/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 742340231
Principal investigator 1 PFIZER INC. $19,065.45 01/28/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 742979091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,549.91 01/28/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-DOSE STUDY IN PATIENTS WITH MODERATE-TO-SEVERE PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP TO ASSESS THE PATIENTS' ABILITY TO SELF-ADMINISTER FASINUMAB USING AN AUTO-INJECTOR AND TO CHARACTERIZE THE PHARMACOKINETICS OF FASINUMAB USING TWO DIFFERENT PRESENTATIONS No dispute reported 06/30/2026 724452913
Principal investigator 1 AstraZeneca Pharmaceuticals LP $68,167.00 01/24/2020 Non-covered Recipient Entity
Pmg Research Inc
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 736741527
Principal investigator 1 SANOFI US SERVICES INC. $847.00 01/23/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 744017687
Principal investigator 1 PFIZER INC. $1,308.16 01/22/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 742937335
Principal investigator 1 PFIZER INC. $3,126.11 01/22/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742979963
Principal investigator 1 Flexion Therapeutics, Inc. $750.54 01/20/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis No dispute reported 06/30/2026 752446097
Principal investigator 1 PFIZER INC. $240.47 01/17/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742979087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,693.74 01/17/2020 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 724451509
Principal investigator 1 SANOFI US SERVICES INC. $255.00 01/17/2020 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 744045309
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $17,337.00 01/16/2020 Non-covered Recipient Entity
PMG RESEARCH INC
EFC-15294 No dispute reported 06/30/2026 752054551
Principal investigator 1 Merck Sharp & Dohme Corporation $5,900.00 01/13/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727113
Principal investigator 1 Novo Nordisk AS $24.99 01/10/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 742340369
Principal investigator 1 Merck Sharp & Dohme Corporation $20.00 01/09/2020 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740727141
Principal investigator 1 GlaxoSmithKline, LLC. $1,998.00 01/08/2020 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734903095
Principal investigator 1 GlaxoSmithKline, LLC. $1,998.00 01/08/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965523561
Principal investigator 1 PFIZER INC. $3,270.40 01/08/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 742935180
Principal investigator 1 PFIZER INC. $29,837.50 01/08/2020 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742979995